<![CDATA[Gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) are common gastrointestinal disorders typically managed with proton pump inhibitors (PPIs). Although effective, PPIs have certain limitations, prompting the development of a new class of acid-suppressing agents known as potassium-competitive acid blockers (P-CABs). These agents offer the potential for faster and possibly more effective treatment compared to PPIs. This literature review aims to evaluate the efficacy, safety, and potential cost-effectiveness of P-CABs versus PPIs in the treatment of GERD and EE, based on five recent clinical trials. This review includes randomized controlled clinical trials investigating four types of P-CABs: vonoprazan, linaprazan glurate, fexuprazan, and tegoprazan, based on five source articles. The findings indicate that all P-CABs demonstrate efficacy that is comparable to or greater than that of PPIs, with a faster onset of action, favorable safety profiles, and promising cost-effectiveness, particularly in severe cases of EE. These results suggest that P-CABs are a promising alternative therapy for GERD and EE, supported by strong clinical evidence across various treatment scenarios. This review offers a novel contribution by summarizing five recent clinical trials on four P-CAB agents. Addressing the lack of comparative evaluations on their efficacy, safety, and cost-effectiveness, especially in PPI-resistant GERD and EE cases, this review supports more informed clinical decision-making.]]>
Copyrights © 2025
